Cargando…

ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients

The objective of this study was to investigate the expression and clinical role of ATP-binding cassette transporter 13 (ABCA13) gene previously shown to be associated with schizophrenia (SZ) through Genome-wide association studies studies. Thirty-two first-episode drug-naive SZ patients and forty-ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Lu, Qin, Yu, Chen, Xinyu, Zhang, Fuquan, Yang, Bixiu, Dong, Kunlun, Wang, Zhiqiang, Zhang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726143/
https://www.ncbi.nlm.nih.gov/pubmed/33299069
http://dx.doi.org/10.1038/s41598-020-78530-9
_version_ 1783620822052634624
author Qian, Lu
Qin, Yu
Chen, Xinyu
Zhang, Fuquan
Yang, Bixiu
Dong, Kunlun
Wang, Zhiqiang
Zhang, Kai
author_facet Qian, Lu
Qin, Yu
Chen, Xinyu
Zhang, Fuquan
Yang, Bixiu
Dong, Kunlun
Wang, Zhiqiang
Zhang, Kai
author_sort Qian, Lu
collection PubMed
description The objective of this study was to investigate the expression and clinical role of ATP-binding cassette transporter 13 (ABCA13) gene previously shown to be associated with schizophrenia (SZ) through Genome-wide association studies studies. Thirty-two first-episode drug-naive SZ patients and forty-eight age and gender-matched healthy controls were enrolled in this study. We measured ABCA13 mRNA expression levels using quantitative real-time PCR at baseline and 12 weeks after antipsychotic therapy. Moreover, clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS) at baseline and 12-week follow-up. We found that ABCA13 mRNA levels were significantly lower in SZ patients compared with healthy controls at baseline. SZ patients’ symptoms were decreased, but ABCA13 mRNA levels were increased after 12 weeks antipsychotic therapy. In addition, there was a significant difference in ABCA13 mRNA levels among SZ patients at baseline and 12-week follow-up. The ABCA13 mRNA levels were not associated with age, BMI, years of education. Of the clinical symptoms measured, the ABCA13 mRNA levels were negatively associated with the PANSS scores at baseline and 12-week follow-up. The results indicated that the ABCA13 mRNA expression level is of interest, and upon further studies, it could be used as a biomarker for SZ treatment outcome.
format Online
Article
Text
id pubmed-7726143
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77261432020-12-14 ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients Qian, Lu Qin, Yu Chen, Xinyu Zhang, Fuquan Yang, Bixiu Dong, Kunlun Wang, Zhiqiang Zhang, Kai Sci Rep Article The objective of this study was to investigate the expression and clinical role of ATP-binding cassette transporter 13 (ABCA13) gene previously shown to be associated with schizophrenia (SZ) through Genome-wide association studies studies. Thirty-two first-episode drug-naive SZ patients and forty-eight age and gender-matched healthy controls were enrolled in this study. We measured ABCA13 mRNA expression levels using quantitative real-time PCR at baseline and 12 weeks after antipsychotic therapy. Moreover, clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS) at baseline and 12-week follow-up. We found that ABCA13 mRNA levels were significantly lower in SZ patients compared with healthy controls at baseline. SZ patients’ symptoms were decreased, but ABCA13 mRNA levels were increased after 12 weeks antipsychotic therapy. In addition, there was a significant difference in ABCA13 mRNA levels among SZ patients at baseline and 12-week follow-up. The ABCA13 mRNA levels were not associated with age, BMI, years of education. Of the clinical symptoms measured, the ABCA13 mRNA levels were negatively associated with the PANSS scores at baseline and 12-week follow-up. The results indicated that the ABCA13 mRNA expression level is of interest, and upon further studies, it could be used as a biomarker for SZ treatment outcome. Nature Publishing Group UK 2020-12-09 /pmc/articles/PMC7726143/ /pubmed/33299069 http://dx.doi.org/10.1038/s41598-020-78530-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Qian, Lu
Qin, Yu
Chen, Xinyu
Zhang, Fuquan
Yang, Bixiu
Dong, Kunlun
Wang, Zhiqiang
Zhang, Kai
ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
title ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
title_full ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
title_fullStr ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
title_full_unstemmed ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
title_short ATP-binding cassette transporter 13 mRNA expression level in schizophrenia patients
title_sort atp-binding cassette transporter 13 mrna expression level in schizophrenia patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726143/
https://www.ncbi.nlm.nih.gov/pubmed/33299069
http://dx.doi.org/10.1038/s41598-020-78530-9
work_keys_str_mv AT qianlu atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT qinyu atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT chenxinyu atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT zhangfuquan atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT yangbixiu atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT dongkunlun atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT wangzhiqiang atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients
AT zhangkai atpbindingcassettetransporter13mrnaexpressionlevelinschizophreniapatients